Aviado · Research
Longevity Daily
Saturday, June 13, 2026
Listen
Today's Brief
Today's digest turns on one central idea: your metabolic age matters more than your birth year. A new study in Alzheimer's & Dementia finds that metabolite-predicted biological age outperforms chronological age in forecasting dementia risk — a signal every health optimizer should act on. A two-year vitamin K2 RCT and fresh mechanistic evidence on phosphatidylcholine round out unusually concrete supplement takeaways. Meanwhile, Life Biosciences' first human dosing of an epigenetic reprogramming therapy and Eli Lilly's $2.75B AI bet on anti-aging signal the arrival of a new clinical era.
10 stories7 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Your Metabolic Age Predicts Dementia Risk Better Than Your Chronological Age
A study in Alzheimer's & Dementia found that when your metabolite-predicted biological age exceeds your chronological age, your risk of vascular dementia, unspecified dementia, and all-cause dementia rises significantly — and disease onset arrives earlier. The research uses metabolomic profiling, which captures the biochemical state of your body rather than simply counting years since birth. For anyone already tracking blood biomarkers, this adds a compelling argument for including metabolomics panels as part of a cognitive aging prevention strategy. The study is observational, so causality isn't established — but the signal is consistent with other biological age research and clear enough to act on.
Read more →A 115-Year-Old Brain With Almost No Neurodegeneration Challenges What We Thought We Knew About Cognitive Decline
A supercentenarian who lived to 115 showed remarkably minimal neurodegeneration at autopsy — directly challenging the prevailing assumption that extreme old age inevitably ends in severe brain pathology. The case, resurfacing in the longevity community following discussion on David Sinclair's podcast, raises a tantalizing question: what protected this brain, and can those mechanisms be identified and replicated? Keep in mind this is a single case study originally published in 2008, not a population-level trial — but the implications for cognitive aging plasticity are hard to ignore.
Read more →Supplements & Compounds
Two-Year RCT: Vitamin K2 (MK-7) Slowed Coronary Artery Calcification Progression by Nearly a Third
A randomized controlled trial in patients with established coronary artery disease found that daily MK-7 supplementation — the most bioavailable form of vitamin K2 — was associated with nearly one-third less progression of coronary artery calcification over 24 months compared to placebo. Coronary artery calcification is one of the strongest predictors of cardiovascular mortality, making this a clinically meaningful endpoint rather than a mere surrogate marker. As an RCT in a high-risk population, this is among the strongest evidence yet for MK-7 as a core supplement in any cardiovascular health or longevity stack.
Read more →Declining Phosphatidylcholine Levels May Be a Hidden Driver of Mitochondrial Aging — And It's Reversible
Researchers found that declining phosphatidylcholine — a phospholipid essential to mitochondrial membrane structure and function — may be a major cause of age-related mitochondrial dysfunction and cellular energy loss. Critically, boosting phosphatidylcholine levels restored more youthful mitochondrial performance. Phosphatidylcholine is available in supplement form via choline compounds and lecithin, giving this early finding immediate relevance to anyone already optimizing their mitochondrial health stack — though larger human trials are still needed to confirm the effect.
Read more →Research & Papers
GLP-1 Drugs Like Semaglutide May Slow Biological Aging, Not Just Promote Weight Loss
University of California researchers have identified multiple mechanisms by which semaglutide may directly influence biological aging — including reducing chronic inflammation, lowering metabolic stress, and dampening the immune hyperactivation that drives accelerated cellular aging. This is mechanistic and observational research rather than a clinical trial with a biological age endpoint, so treat it as hypothesis-generating for now. But for the tens of millions already taking GLP-1 drugs, the evidence for broader systemic benefits well beyond weight loss continues to build.
Read more →Social Disadvantage Accelerates Epigenetic Aging as Powerfully as Lifestyle Factors
A meta-analysis synthesizing 1,065 effect sizes across 140 independent studies confirms that social disadvantage — poverty, discrimination, neighborhood deprivation — measurably accelerates biological aging at the epigenetic level. The scale of this synthesis makes it the strongest evidence yet that social stressors belong in the same tier as diet and exercise when thinking about biological age drivers. For health optimizers, this is a reminder that managing psychological and social stress isn't soft self-care — it directly shifts the rate at which your epigenome ages.
Read more →Aviado Research: A Deep Dive Into the Evidence Behind Longevity Science
This featured analysis from Aviado Research examines the current evidence landscape in longevity science, separating what the data actually supports from what remains premature or overhyped. Aviado's research team brings independent, unbiased perspective to the interventions most relevant to health-conscious individuals serious about long-term healthspan. Read the full analysis for a rigorous, practical breakdown of where the science stands today.
Read the full Aviado analysis →Lifestyle & Nutrition
Two Common Strength Tests Predict Longevity — Top Performers Had 37% Lower Mortality Risk
New York researchers found that people who scored best on two simple physical strength tests had a 37% lower risk of death than those who scored worst — a striking gap from inexpensive, no-equipment assessments. Muscle strength has long been a proxy for biological resilience, and this adds to a growing body of evidence that functional fitness stratifies longevity risk better than many costly biomarkers. The takeaway is clear and actionable: building and maintaining strength, and regularly testing grip and lower-body power, should be a non-negotiable part of any serious longevity protocol.
Read more →Industry & Policy
Life Biosciences Doses First Human in the World's First Epigenetic Reprogramming Trial
Life Biosciences — co-founded by Harvard geneticist David Sinclair — has dosed the first participant in a Phase 1 trial of ER-100, a gene therapy designed to restore aged cells to a more youthful epigenetic state, initially targeting optic neuropathies including glaucoma and NAION. This marks the first-ever FDA-cleared test of partial epigenetic reprogramming in humans. Phase 1 is focused on safety only and results are years away — but the technology moving from lab to clinic is a genuine watershed moment for the longevity field.
Read more →Eli Lilly's $2.75 Billion AI Bet on Anti-Aging Drugs Signals Big Pharma's Longevity Pivot
Eli Lilly's $2.75 billion investment in Insilico Medicine's AI-powered drug discovery represents the largest institutional commitment yet to treating aging as a primary pharmaceutical target. The deal is paired with Insilico's launch of the industry's first formal Longevity Board — a scientific oversight body dedicated to AI-enabled aging research — signaling that anti-aging is moving from the fringe to the center of mainstream pharma strategy. For the longevity ecosystem, this scale of Big Pharma capital flowing into the space is the strongest sector validation signal we've seen.
Read more →